Merche Gironella

Just in: Good news for the myeloma field. FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy. Note: Always use Tec-Dara with monthly IVIG. It’s not optional. That was fast! And this is unprecedented curve is why.

Review: Extramedullary Multiple Myeloma onlinelibrary.wiley.com/doi/full/10.11…

Just out in @NEJM Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos Link: nejm.org/doi/full/10.10… More in thread

Ampliamos equipo! Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪 Te apuntas? (Contactar secretaria-hemato@vhio.net)

S'ha fet el curs sobre Mieloma múltiple, centrat en la millora de l’atenció a pacients en recaiguda. 🎯 Objectius: identificar necessitats, avaluar alternatives terapèutiques, detectar toxicitats i prevenir complicacions. Enhorabona per la feina feta! 👏

Congratulations InmaFernandez for the poster presented at #IMS @Hemato_Vhebron

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma #mmsm #bmtsm @NatRevClinOncol nature.com/articles/s4157…

Andromeda data after 5 years, very reassuring! #EHA2025

CONGRESS | #EHA2025 | Evangelos Terpos @uoaofficial shares the latest update to the EHA-EMN clinical practice guidelines for diagnosis, treatment, and follow-up. Key updates include new guidelines on defining high-risk disease, examinations upon diagnosis, monitoring for SMM, quadruplet regimens in NDMM, targeted therapies in early relapse and sequencing immunotherapies. Follow our live feed for more updates: loom.ly/hq6n5HU #mmsm #myeloma #MedEd #MedNews

CONGRESS | #ASCO25 | Suzanne Trudel @pmcancercentre discusses MRD negativity from the DREAMM-8 trial of belamaf plus Pd vs PVd for R/R #MultipleMyeloma. BPd was associated with increased rates of CR-based MRD negativity and MRD negativity was associated with PFS and OS benefits across key subgroups. Follow our live feed for more updates: loom.ly/s_RkmMc #mmsm #myeloma #MedicalCongress

Presented at #ASCO25: In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results: nej.md/4mkaecR @ASCO

The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! ⁦@JCO_ASCO⁩ ⁦@TheIACH⁩ ⁦@COMyCongress⁩

Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly reduced CRS, no ICANS seen. #ASCO25

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance @iStopMM @JAMAOnc #mmsm jamanetwork.com/journals/jamao… Important data coming to support need for new ranges of normal free light chains based on eGFR👇

Macroglobulinemia de Waldeström- Tratamiento Selección del Esquema según los síntomas del pacientes y los posibles #EAs de los medicamentos @Fer_martinmoro @HematoRYC en #AgoraH25 #HematoEnRed @sehh_es @SEHHJoven

Brief Report: CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma (CARTITUDE-4 trial) nej.md/4gA6G27 #Hematology

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 @thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

Approach to MGUS + neuropathy - Rule out more common causes of peripheral neuropathy - Rule out MM/WM/AL amyloidosis - Consider MGUS associated neuropathies: type 1 cryogenic, CIDP mimickers (DADS-M, MADSAM, POEMS, CANOMAD)

CONGRESS | #IMS2024 | PRESENTATION María-Victoria Mateos @mvmateos shares a study update from the phase III CARTITUDE-4 trial comparing cilta-cel with SOC in lenalidomide (Len)-refractory MM (N=419 randomized; N=176 received cilta-cel as study tx). Cilta-cel significantly improved OS, with 76.4% vs 68.8% OS rates at 30 months, more than doubled MRD negativity rates, and significantly improved QOL. Follow our live feed for more updates: multiplemyelomahub.com/medical-inform… #mmsm #myeloma #MedicalCongress

#NotaDePrensaSEHH | Los tumores hematológicos ocupan la quinta posición de la lista de cánceres más frecuentes en España. ➕información bit.ly/3Vddfkf @_pethema @geltamo @mvmateos @amgarciasancho @rc_Girona @rmarcosgragera #SEHHematología #MesDelCáncerSanguíneo